NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ZENITHDRUG · data 2026-11-01
Zenith Drugs Ltd.
In plain words
Price: 42.3% below its 52-week high of ₹64.1.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹171 cr |
| Net profit (last 12 months) | ₹4 cr |
| Sales growth, 3 years (yearly) | 14.3% |
| Profit growth, 3 years (yearly) | -8.5% |
At a glance
P/E 16.1, P/B 0.9, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 5.5%, ROCE 9.3%, operating margin 3.6%: how much profit it earns on the money it uses.
Debt/equity 0.75, Profit growth -8.5% and sales growth 14.3% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (5.5%).
- Thin operating margin (3.6%).
- Profit fell 8.5% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal
- 16 Sept 26Deal Bulk deal: BINDU GARG bought ₹0.79 cr (net ₹0 cr) -5.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Zenith Drugs Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.75.
What is Zenith Drugs Ltd.'s P/E ratio?
About 16.1, based on the last 12 months' earnings and a price of ₹37 (data 2026-11-01).
What is the 52-week high and low of Zenith Drugs Ltd.?
The 52-week high is ₹64.1 and the 52-week low is ₹33.3.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Zenith Drugs Ltd. | ₹37 | ₹63 cr | 16.1 | 0.9 | 5.5% | 9.3% | 0.75 | -40.5% |
| Vilin Bio Med Ltd. | ₹52.05 | ₹73 cr | 40.9 | 2.8 | 7.5% | 11.3% | 0.01 | +106.5% |
| Sunil Healthcare Ltd. | ₹61.55 | ₹70 cr | 17.7 | — | 5.9% | 6% | 0.8 | -13.3% |
| Onyx Biotec Ltd. | ₹36 | ₹65 cr | — | — | -0.4% | 0.5% | 0.27 | -12.4% |
| Vivimed Labs Limited | ₹5.53 | ₹51 cr | — | — | — | -43.6% | — | +5.3% |
| Biofil Chemicals & Pharmaceuticals Ltd. | ₹28.68 | ₹47 cr | 96.4 | — | 13.8% | 1.8% | 0.14 | -27.5% |
Compare ZENITHDRUG with VILINBIO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ZENITHDRUG in NSE Scanner →